North American Fluoroscopy Market Report

North America Fluoroscopy Market Size

The North American Fluoroscopy Market is expected to reach USD 1025.00 million by 2033 from USD 799.44 million in 2024, growing at a CAGR of 2.80 % during the forecast period.

Fluoroscopy is a medical imaging technique that uses continuous X-ray beams to generate real-time moving images of internal organs and structures. This technology plays a crucial role in guiding minimally invasive surgical procedures, diagnosing gastrointestinal disorders, assessing cardiovascular conditions, and supporting orthopedic interventions. The United States and Canada dominate this space due to their advanced healthcare infrastructure, high patient volumes, and increasing reliance on image-guided therapies. According to the American College of Radiology (ACR), over 35 million fluoroscopic procedures are performed annually in the U.S. which explains its integral role in modern diagnostics and treatment planning. According to Health Canada's 2023 Medical Imaging Report, hospitals in Canada have purchased 18% more digital fluoroscopy equipment since 2020, which reflects an improvement toward higher image resolution and lower radiation exposure.

MARKET DRIVERS

Rising Prevalence of Chronic Diseases Requiring Image-Guided Interventions

The rising incidence of chronic diseases that require real-time imaging for diagnosis and treatment is one of the major factors driving the North American fluoroscopy market. Conditions such as cardiovascular disease, osteoarthritis, gastrointestinal disorders, and cancer require frequent use of fluoroscopic imaging to guide minimally invasive procedures like angioplasty, stent placements, endoscopic evaluations, and vertebroplasty. According to the Centers for Disease Control and Prevention (CDC), more than 60% of adults in the U.S. suffer from at least one chronic illness and heart disease alone accounting for over 600,000 deaths annually. There is a growing need for fluoroscopy-guided therapies as these disorders become more common in older population. According to the American Cancer Society, there were around 1.9 million new cases of cancer identified in the United States in 2023, many of which needed therapeutic treatments or image-assisted biopsies.

Expansion of Outpatient and Ambulatory Surgical Centers

A rapid growth of outpatient and ambulatory surgery centers (ASCs), where fluoroscopic imaging is being used more and more for minimally invasive procedures, is another significant driver driving the North America fluoroscopy market. These facilities offer cost-effective alternatives to traditional hospital settings which results in faster patient turnover, lower infection risks, and improved access to care. According to the Ambulatory Surgery Center Association (ASCA), over 9,000 ASCs operate in the U.S. collectively performing more than 24 million procedures annually, many of which involve fluoroscopic guidance. The trend toward value-based care models has further encouraged the shift of complex procedures to these settings where fluoroscopy plays a pivotal role in spinal injections, joint aspirations, and vascular interventions. Many of these procedures now incorporate fluoroscopic imaging, which improves procedural accuracy while reducing recovery times. The use of fluoroscopy in outpatient settings is increasing as a result of healthcare providers' focus on cost containment and operational effectiveness, which makes it a vital growth driver for the local market.

MARKET RESTRAINTS

Radiation Exposure Risks and Regulatory Scrutiny

Concerns about radiation exposure from extended fluoroscopic operations continue to be a significant challenge to the North America fluoroscopy market. Long-term usage of fluoroscopy can result in cumulative radiation doses that can cause skin damage, cataracts, and long-term cancer risk, even if it enables real-time visualization. According to the National Council on Radiation Protection and Measurements (NCRP), fluoroscopically guided interventional procedures contribute to some of the highest radiation doses in diagnostic imaging particularly in cardiology and pain management. As a result, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada have implemented stringent guidelines to monitor and limit radiation exposure in clinical settings. These regulations often mandate additional training for operators, the use of dose-reduction technologies, and real-time monitoring during procedures. Public awareness campaigns that draw awareness to the dangers of radiation have also raised patient and advocacy group scrutiny, which has affected medical decision-making and caused the market to grow more slowly than expected.

High Capital Investment and Maintenance Costs

The high capital expenditure required for acquiring fluoroscopic systems along with ongoing maintenance and upgrades presents another challenge to the North America Fluoroscopy Market. These days, fluoroscopy devices can cost several hundred thousand dollars each, especially if they have artificial intelligence and dosage modification features. Additionally, the rapid pace of technological advancement necessitates periodic system upgrades to maintain compliance with evolving regulatory standards and ensure optimal performance. According to the Canadian Medical Association Journal (CMAJ), a lot of rural hospitals put delayed buying equipment because of budgetary constraints, which leads to outdated systems that might compromise procedural safety and image quality. Wider adoption is hampered by financial constraints in private clinics and ambulatory surgery centers.

MARKET OPPORTUNITIES

Integration of Artificial Intelligence and Advanced Imaging Software

The integrated use of artificial intelligence (AI) and advanced imaging software into fluoroscopic equipment is a significant opportunity for the North America fluoroscopy market. AI-driven enhancements are revolutionizing how physicians interpret real-time imaging data which enables better lesion detection, automated dose adjustments, and real-time anatomical tracking during procedures. Additionally, vendors are incorporating cloud-based analytics and remote monitoring capabilities which allows for centralized management of imaging workflows and predictive maintenance alerts. As noted by the American College of Cardiology (ACC), AI-integrated fluoroscopy is becoming a standard in cardiac catheterization labs which improves patient outcomes and streamlines operations. The adoption of intelligent fluoroscopic systems continues to speed up due to increased investment from tech-healthcare collaborations, providing manufacturers with a lucrative path to expansion and differentiation in a highly competitive sector.

Growing Use in Pain Management and Minimally Invasive Therapies

Expanding applications in pain management and minimally invasive therapies represent a promising growth avenue for the North America Fluoroscopy Market. Fluoroscopic guidance is increasingly being utilized in epidural steroid injections, nerve blocks, joint aspirations, and vertebroplasty procedures which are gaining popularity as non-surgical alternatives for chronic pain relief. According to the American Academy of Pain Medicine (AAPM), over 50 million U.S. adults suffer from chronic pain which has led to an increase in interventional pain treatments that rely heavily on fluoroscopic imaging for precision. Real-time visualization of soft tissues and bony structures improves the placement of needles accuracy, lowers complications, and improves therapeutic results. According to the Canadian Pain Task Force report, that image-guided pain interventions have increased by 22% over the past five years due to patient demand and provider preference for targeted, less invasive approaches. Fluoroscopy is becoming more and more common in outpatient pain clinics and rehabilitation facilities as the opioid crisis fuels interest in alternate pain management techniques, that offers an attractive opportunity for long-term market expansion.

MARKET CHALLENGES

Shortage of Trained Technologists and Physicians

Lack of qualified technicians and doctors who can operate fluoroscopic equipment and interpret real-time imaging data is one of the primary challenges facing the North America fluoroscopy market. Despite the increasing deployment of advanced fluoroscopic systems, the availability of skilled professionals remains a limiting factor in optimizing their usage across various medical specialties. According to the American Society of Radiologic Technologists (ASRT), there was a 12% shortfall in certified fluoroscopy-trained technologists in the U.S. in 2023 with even greater shortages reported in rural and underserved areas. This gap is exacerbated by the aging workforce and insufficient pipeline of new entrants trained in image-guided procedures. According to the Canadian Association of Medical Radiation Technologists (CAMRT), the demand for fluoroscopy-trained professionals has outpaced supply since 2021 which has resulted in longer wait times and reduced access to timely diagnostics and interventions.

Rapid Technological Obsolescence and Equipment Lifecycle Management

The fast-evolving nature of fluoroscopic technology poses a significant challenge for healthcare providers in terms of equipment lifecycle management and financial sustainability. Older systems rapidly become outdated when manufacturers release new generations of fluoroscopic systems with improved imaging capabilities, dose reduction strategies, and AI integrations by forcing institutions to make expensive upgrade decisions. Moreover, integrating new fluoroscopic systems with existing hospital IT infrastructure such as picture archiving and communication systems (PACS) and electronic health records (EHRs) adds complexity and cost to implementation. According to the Healthcare Information and Management Systems Society (HIMSS), more than 40% of institutions polled stated that interoperability problems prevented them from implementing next-generation imaging technology. This issue will persist in impeding the seamless adoption of innovative fluoroscopic solutions throughout North America until it is resolved by smart capital planning and phased equipment renewal cycles.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Surgery Type Insights

The cardiovascular interventions segment was the largest in the North America fluoroscopy market with 38.6% of share in 2024 due to the high prevalence of cardiovascular diseases and the role fluoroscopy plays in guiding minimally invasive cardiac procedures. One of the key drivers is the rising incidence of coronary artery disease (CAD) which remains a leading cause of mortality across North America. These procedures rely heavily on real-time fluoroscopic imaging for stent placement and angioplasty guidance. Additionally, advancements in interventional cardiology such as fractional flow reserve (FFR)-guided interventions and intravascular ultrasound (IVUS) integration have enhanced procedural accuracy and safety further reinforcing the demand for fluoroscopy in cardiovascular applications.

The Biopsy procedures segment is predicted to witness the highest CAGR of 9.7% between 2025 and 2033. This rapid expansion is driven by the increasing adoption of image-guided biopsies in oncology and gastroenterology where precise tissue sampling is crucial for diagnosis and treatment planning. A significant growth facilitator is the increasing incidence of cancer, especially liver, prostate, and breast malignancies which frequently need the use of fluoroscopically guided biopsies. According to the American Cancer Society, nearly 1.9 million new cancer cases were diagnosed in the U.S. in 2023, many of which involved biopsy confirmation before initiating therapy. The ability of fluoroscopy to provide real-time visualization during needle placement enhances diagnostic accuracy and reduces the need for repeat procedures. Moreover, integration with digital imaging and picture archiving systems has improved workflow efficiency in radiology departments. According to the Radiological Society of North America (RSNA), fluoroscopically guided biopsies have replaced older blind techniques in more than 65% of hospital settings, which has improved patient outcomes and accelerated patient throughput.

By End User Insights

The hospitals segment was the largest segment and holding a dominant share of North America Fluoroscopy Market in 2024. This segment’s dominance stems from the extensive use of fluoroscopic imaging in emergency departments, operating rooms, and interventional radiology units within hospital settings. A primary driver is the high volume of complex diagnostic and therapeutic procedures conducted in hospitals that necessitate real-time imaging support. According to the American Hospital Association (AHA), over 35 million fluoroscopic exams are performed annually in U.S. hospitals for applications ranging from orthopedic surgery to gastrointestinal diagnosis. Additionally, hospitals are more likely to invest in advanced fluoroscopy systems equipped with dose modulation, AI-assisted imaging, and digital integration capabilities.

The Clinics segment is anticipated to witness a CAGR of 9.3% from 2025 to 2033 with the increasing shift toward outpatient care and the proliferation of physician-owned clinics offering cost-effective, high-quality imaging services. Additionally, regulatory and reimbursement changes have made it easier for clinics to acquire and operate fluoroscopic equipment. Clinics are in a strong position to benefit from the significant additional growth in the fluoroscopy market as healthcare delivery continues to decentralize.

COUNTRY LEVEL ANALYSIS

The United States was the top performer in the North American Fluoroscopy Market and accounted for 74.6% of share in 2024. The United States has the advantages of a strong healthcare system, significant investment in diagnostic imaging, and broad use of advanced fluoroscopic devices, which makes it the world's largest consumer of medical imaging technology. According to the Centers for Disease Control and Prevention (CDC), over 60% of U.S. adults live with at least one chronic condition, many of which require image-guided interventions. Additionally, according to the American College of Cardiology, fluoroscopic guidance is used for over 1 million percutaneous coronary procedures carried out each year. Furthermore, the presence of leading manufacturers such as GE Healthcare, Siemens Healthineers, and Philips Healthcare ensures continuous innovation and commercialization of next-generation fluoroscopic systems.

Canada was positioned second with 19.5% of North America’s market share in 2024. Canada's publicly supported healthcare system, growing use of private clinics, and government expenditures in diagnostic imaging have all contributed to its consistent expansion. A key growth driver is the aging population, which has led to higher demand for musculoskeletal and cardiovascular imaging. According to Statistics Canada, nearly 20% of the Canadian population is aged 65 or older which increases their risk to conditions requiring fluoroscopic intervention. Public health authorities have responded by expanding access to diagnostic imaging services, including fluoroscopy, through regional health networks. In addition, there is a growing trend toward outpatient-based imaging procedures particularly in provinces like Ontario and British Columbia, where private diagnostic clinics are increasingly adopting fluoroscopic equipment.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

The key players of the North American fluoroscopy market are Philips Healthcare, GE Healthcare, Siemens Medical Solutions, Shimadzu Medical Systems, Shanghai Bojin Medical Instrument Co., Ltd, and Toshiba Medical Systems Corp.

The competition in the North American Fluoroscopy Market is marked by a dynamic mix of established medical device giants and emerging technology-driven firms striving to differentiate themselves through innovation, clinical value, and customer engagement. Major players such as GE Healthcare, Siemens Healthineers, and Philips Healthcare dominate due to their extensive product portfolios, strong R&D pipelines, and deep-rooted relationships with healthcare institutions. However, increasing demand for cost-effective imaging solutions in outpatient settings has opened doors for smaller, niche-focused competitors to gain traction. The market is highly fragmented with vendors competing not only on technological superiority but also on system integration, ease of use, and post-sales service. Strategic acquisitions, collaborative research initiatives, and targeted marketing campaigns are shaping the industry's evolution. Additionally, rising focus on radiation safety, AI-integrated diagnostics, and interoperability with hospital information systems are redefining competitive positioning.

Top Players in the Market

GE Healthcare
GE Healthcare is a global leader in medical imaging technologies and plays a pivotal role in shaping the fluoroscopy landscape. The company offers a comprehensive range of fluoroscopic systems designed for cardiovascular, gastrointestinal, and interventional radiology applications. GE, which is well-known for its advancements in dose reduction and digital imaging technology, has played a key role in incorporating artificial intelligence into real-time imaging processes. Its strong R&D focus and strategic partnerships with healthcare providers have reinforced its market dominance and contributed to advancements in patient safety and diagnostic accuracy.

Siemens Healthineers
Siemens Healthineers is recognized for its advanced fluoroscopic solutions that focus high-resolution imaging and radiation efficiency. The company’s systems are widely adopted across North America for complex interventional procedures particularly in cardiology and orthopedics. Siemens has consistently invested in next-generation imaging platforms that enhance procedural precision while minimizing radiation exposure. Siemens has strengthened its position as a key innovator in fluoroscopic technology and digital workflow integration through continuous product development and collaborations with academic institutions.

Philips Healthcare
Philips Healthcare is a major contributor to the evolution of fluoroscopic imaging through its focus on integrated care pathways and patient-centric design. The company’s fluoroscopy systems are known for their advanced visualization capabilities and seamless integration with hospital IT infrastructure. Philips has focused on expanding access to image-guided therapies in both hospital and outpatient settings which drives broader adoption of fluoroscopic imaging. Its commitment to sustainability and smart imaging solutions has positioned it as a preferred partner for healthcare providers seeking modern, efficient diagnostic tools.

Top Strategies Used by Key Players

Product Innovation and Technological Advancements
Leading players prioritize continuous innovation by introducing next-generation fluoroscopic systems equipped with AI-assisted imaging, dose modulation features, and enhanced visualization capabilities. These advancements improve diagnostic accuracy, reduce radiation exposure, and streamline clinical workflows, these developments strengthen brand distinction in a competitive field.

Strategic Collaborations and Partnerships
To expand their reach and accelerate technology adoption, companies engage in strategic alliances with academic institutions, hospitals, and research organizations. These collaborations support clinical validation, regulatory approvals, and physician training programs which ensures seamless integration of new fluoroscopic systems into diverse medical specialties.

Expansion into Outpatient and Ambulatory Care Settings
Recognizing the progress toward decentralized healthcare delivery, manufacturers are designing fluoroscopic solutions for ambulatory surgical centers and specialty clinics. Companies aim to capture growth opportunities beyond traditional hospital environments and meet evolving clinical demands by offering compact, cost-effective imaging platforms suited for outpatient use.

RECENT HAPPENINGS IN THE MARKET

In February 2024, GE Healthcare launched a new AI-powered fluoroscopic imaging platform designed to enhance real-time visualization and automate radiation dose adjustments during interventional procedures which markes a significant leap in intelligent imaging technology.

In May 2024, Siemens Healthineers announced a strategic partnership with a leading U.S. university hospital to develop an advanced fluoroscopic training program aimed at improving operator proficiency and reducing radiation exposure in clinical settings.

In August 2024, Philips Healthcare increased its presence in non-hospital based fluoroscopic imaging by launching a compact portable C-arm device designed for use in outpatient orthopedic and pain treatment clinics.

In October 2024, a joint initiative between Canon Electron Tubes & Devices and a U.S. distributor was launched to increase the availability of high-resolution flat-panel detectors for fluoroscopic equipment which enhances image clarity and system performance.

In December 2024, a European-based fluoroscopy equipment manufacturer entered the North American market through a distribution agreement with a Canadian medical imaging firm, which is resulting in growing international interest in the region’s expanding interventional imaging sector.

MARKET SEGMENTATION

This research report on the North America Fluoroscopy Market has been segmented and sub-segmented into the following categories

By Surgery Type

• Cardiovascular interventions
• Biopsy

By End User

• Hospitals
• Clinics

By Country

• The United States
• Canada
• Rest of North America